UW-founded cancer immunotherapy developer Neoleukin Therapeutics will merge with Aquinox in an all-share deal giving the spinout's shareholders roughly 38.6% equity in the new company.

3-V Biosciences has changed its name to Sagimet Biosciences after closing a series E round backed by strategic partner Ascletis at $25m.

Existing investor McKesson Ventures co-led the $22.5m round, which will enable IVX Health to open additional infusion and injection therapies centres.

Huadao Biopharma has collected a $14.5m series B investment from NKY Medical Holdings to build out its cancer treatment technology.

MedWhat's request to replace a judge hearing the case against Stanford-StartX Fund has been refused and the company has been ordered to pay costs for blocking discovery.

Cancer treatment developer Rakuten Medical has received $100m in series C1 capital from affiliate Rakuten, which now holds a 22.6% stake.

Alphabet and Celgene are among the investors facing a delayed exit from Rapt Therapeutics, which has postponed an initial public offering that would have raised up to $80m.

Harvard Medical School's Beth Israel Deaconess Medical Center has appointed MIT TLO's Tod Woolf as executive director of the Technology Ventures Office.

Legend Capital and Xiamen C&D have contributed to a nine-figure renminbi round that will fund international growth and R&D for dentistry services provider Bondent Technology.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.